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Abstract 
Background: To evaluate the promoter methylation status of RECK gene and mRNA expression 
in patients with hepatocellular carcinoma (HCC). 
Methods: We analyzed RECK methylation by MSP, and RECK mRNA by real-time PCR in 74 
HCC. The liver cell lines (7721, Chang and Hep-G2) were treated with 5-Aza-CdR and TSA. 
Results: RECK mRNA were lower in HCC tissues (Mean  -∆Ct = -3.29) than that in Non-Hcc 
tissues (Mean -∆Ct = -2.42). Expression of RECK was elevated in only 24 (32.43%) of the 74 HCC 
patients but decreased (-∆∆Ct<0) in 50 (67.57%) of the patients. RECK promoter was hyper-
methylated in 55.4% (41/74) of HCCs, and in only 17.6% (13/74) of Non-Hcc samples. RECK 
mRNA were lower in HCC patients with hypermethylation (∆MI>=0.5) (Mean -∆∆Ct = -1.75) than 
those with demethylation (∆MI<0.5) (Mean -∆∆Ct = 0.05), and there is a decreased tendency for 
RECK mRNA in HCC patients with promoter hypermethylation (p = 0.002). There was a signif-
icantly correlation found between RECK mRNA and poor survival after surgery. After treated by 
5-Aza-CdR and TSA, we found that RECK mRNA induced different changes in 7721, Chang and 
Hep-G2 cells. And RECK demethylation also induced by epigenetic inhibitors. 
Conclusion: The results suggested that the hypermethylation may lead to promoter silencing of 
RECK mRNA and associated with poor survival in HCC. 
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Introduction 
The  reversion-inducing  cysteine-rich  protein 
with Kazal motifs (RECK) is anchored to the cell sur-
face  via  glycosylphosphatidylinositol,  which  can 
suppress  tumour  invasion  and  metastasis  through 
involving in breakdown of the extracellular matrix [1]. 
RECK  modulates  the  function  of  MT1-MMP  in  di-
rectly inhibiting its proteolytic activity and modulat-
ing the endocytic pathway. Hence, RECK could play a 
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key role of tumor suppression by involving the regu-
lation  of  angiogenesis  and  maintenance  of  vascular 
integrity [2]. 
RECK  appears  to  down-regulation  and  have  a 
good  prognostic  significance  across  several  cancers. 
Reduced RECK expression was an independent and 
significant  factor  to  predict  a  poor  prognosis  in 
Non-small-cell  lung  carcinoma,  colorectal  cancer, 
pancreatic cancer, and gastric cancer [3-6]. The level 
of RECK gene expression is inversely correlated with 
histological  grade,  infiltrative  depth  and  lymphatic 
metastasis  in  esophageal  squamous  cell  carcinoma 
(ESCC) [7]. The breast carcinoma patients whose tu-
mors exhibited low levels of RECK had a poor 5-year 
RFS rate than those with high RECK expression [8]. 
RECK displays as a metastasis suppressor in cholan-
giocarcinoma, and upregulation of RECK expression 
could  provide  a  potential  therapy  to  improve  the 
prognosis [9]. 
There  are almost  certainly  pathways  by  which 
RECK is down-regulated in cancer. Hypoxia induces 
RECK  downregulation  through  the  recruitment  of 
HDAC1 and HIF-1α to the rHRE2 site in the promoter 
and the inhibition of hypoxic RECK silencing would 
be a therapeutic and preventive target for early tu-
morigenesis. However, the CpG island promoter hy-
permethylation is associated silencing of tumor sup-
pressor  genes,  which  is  the  most  recognized  epige-
netic disruption in human tumors [10]. RECK down-
regulation  is  caused  by  promoter  methylation  in 
metastatic  non-small  cell  lung  cancer  and  promoter 
methylation was also detected in human lung cancer 
cell lines [11]. Hypermethylation of RECK promoter is 
also a common event in human ESCC, which occurs 
concurrently in tumor–adjacent normal mucosa and is 
correlated with poor prognosis in ESCC patients [12]. 
It  implied  that  the  promoter  methylation  of  RECK 
could play a particularly important regulatory role for 
RECK expression in carcinogenesis.  
The molecular mechanisms behind RECK tran-
scriptional regulation are clearly complex, and are still 
yet  to  be  fully  defined.  So  far  the  few  studies  con-
ducted focused on RECK methylation and no data are 
available regarding RECK in HCC. The purpose of the 
study was to investigate the relationship between the 
expression  of  RECK  and  promoter  methylation  in 
HCC,  and  determined  the  effects  of  Trichostatin  A 
(TSA)  treatment  on  the  methylation  status  and  ex-
pression level of the RECK gene in liver cell lines.  
Materials and methods 
Patients and tissue samples 
This  study  was  approved  by  our  institutional 
review board. A total of 74 patients with HCC who 
underwent  complete  tumor  resection  at  the  Second 
Military  Medical  University  between  January  2008 
and December 2009 and whose histological specimens 
were  available  for  immunohistochemical  staining 
(IHS)  were  retrospectively  reviewed.  The  patients 
consisted  of  65  men  and  9  women,  ranging  in  age 
from 27 to 70 years (mean ± SD, 49.51 ± 11.12 years). 
All  tumors  were  histologically  diagnosed  as  HCC 
according  to  the  Edmondson-Steiner  classification 
system  [13].  In  all  cases,  H&E-stained  slides  were 
re-examined  independently  by  three  experienced 
pathologists without any knowledge of clinical data. 
The matched Non-Hcc tissues were obtained from the 
liver >3 cm away from tumors and were confirmed to 
be  free  of  tumor  by  microscopic  examination.  The 
frozen tissue samples were flash frozen in liquid ni-
trogen  immediately  after  surgical  resection  until 
analysis. 
Cell Culture and Treatment 
The  liver  cell  lines  (7721,  Chang  and  Hep-G2) 
were kept in our laboratory. The cells were cultured in 
RPMI medium plus 10% fetal bovine serum in a hu-
midified  37°C  incubator  containing  5%  CO2.  They 
were plated and treated with final concentration of 10 
µM 5-Aza-2’-deoxycytidine (5-Aza-CdR, Sigma) and 
400  ng/ml  TSA.  The  fresh  medium  was  changed 
every 24 hours to maintain the 5-Aza-CdR and TSA 
concentration. RNA  was isolated 3 days after treat-
ment. 
Methylation analysis of RECK 
Genomic  DNA  was  isolated  by  Commercial 
QIAamp DNA Mini kit (QIAGEN, Hilden, Germany). 
The bisulfite modification of DNA was done accord-
ing to described previously [14]. RECK methylation 
was measured using a methylation-specific PCR assay 
as previously described [15]. Primers used were: un-
methylated  RECK  forward  primer,  5’- 
TAAAGAGTTTTGGTATGGGGTATGT-3’,  reverse 
primer, 5’- CTCCA AACCACAAAATACTCAAA-3’; 
methylated  RECK  forward  primer,  5’- 
AATAAAGAGTTTTGGTACGGGGTAC-3’,  reverse 
primer, 5’- AAAACCGCGAAATACTCGAA-3’. Two 
microliter of  modified  genomic  DNA samples  were 
PCR amplified in a total volume of 50 μl. The PCR was 
performed in a thermal cycler for 40 cycles consisting 
of denaturation at 95°C for 30 sec, annealing at 58°C 
for 30 sec, and extension at 72°C for 30 sec, followed 
by a final 10 min extension. The PCR products were 
separated  on  2%  agarose  gels  and  visualized  using 
ethidium  bromide  staining.  The  methylation  index 




mula: 100 x methylated reaction/(unmethylated reac-
tion  +  methylated  reaction)  [16].  ΔMI  defined  as 
MIHCC - MINon-Hcc. 
Quantitative real-time PCR analysis for RECK 
Total RNA was isolated from 74 HCC, adjacent 
normal tissues, and cultured cells. In brief, total RNA 
was extracted with TRIzol reagent, according to the 
protocol provided by the manufacturer. The quantity 
and  quality  of  the  RNA  samples  were  measured 
carefully  by  spectrophotometer  and  electrophoresis. 
The first-strand cDNA was synthesised from 2 μg of 
total  RNA.  Primer  sequences  of  RECK  for  reverse 
transcription-PCR  (RT-PCR)  reaction  were  forward 
(5’- CCTCAGTGAGCACAGTTCAGA-3’) and reverse 
(5’- GCAGCACACACACTGCTGTA-3’)  [15].  Quan-
titative  real-time  PCR  (qPCR)  were  carried  out  by 
using the Mx3000P QPCR System (Stratagene, USA). 
The cDNA was then used for qPCR in a 20 μl SYBR 
Premix  Ex  Taq.  qPCR  for  RECK  mRNA  expression 
was performed under the following conditions: 5 min 
at 95°C, 40 cycles of 30 seconds at 95°C, 30 seconds at 
60°C,  and  1min  at  72°C.  As  an  internal  control  for 
qPCR, β-actin mRNA expression was amplified from 
the same cDNA samples. All results were normalized 
to β-actin amplification. CT values for triplicate reac-
tions  were  averaged  and  relative  RECK  expression 
was  determined  with  the  comparative  CT  method, 
using average CT values for RECK and β-actin. 
Statistical analysis  
All data were generated without knowledge of 
the  clinical  status  of  the  samples  analyzed  by  SPSS 
17.0 software (SPSS, Inc., Chicago, USA). Associations 
between categorical variables were examined by us-
ing  the  Pearson  χ2  and  Fisher  exact  tests. 
Kaplan–Meier  analysis  and  the  log  rank  test  were 
performed to identify survival differences in HCC. A 
p value of less than 0.05 was considered statistically 
significant. 
Results 
The levels of RECK mRNA in HCC and cor-
responding Non-Hcc tissues 
To accurately quantify relatively RECK mRNA 
levels, we used a real-time PCR assay in 74 HCC and 
matched  Non-Hcc  tissues.  Overall  results  of  RECK 
mRNA  are  summarized  in  Fig.  1.  We  found  that 
RECK mRNA expression lower in HCC tissues (Mean 
-∆Ct = -3.29; 95%CI, -4.23 – -2.36) than that in Non-Hcc 
tissues (Mean -∆Ct = -2.42; 95%CI, -3.27 – -1.54). There 
was a significant difference was found in RECK ex-
pression  between  HCC  tissues  and  matching 
Non-Hcc tissues (p = 0.005; Fig.1A). There was a de-
creased tendency for RECK expression from Non-Hcc 
tissues  to  HCCs,  and  more  HCC  samples  showed 
lower RECK expression (Fig. 1B). Expression of RECK 
was elevated (-∆∆Ct>=0) in only 24 (32.43%) of the 74 
HCC patients but decreased (-∆∆Ct<0) in 50 (67.57%) 
of the patients (Fig. 1C). It suggests that RECK genes 




Fig. 1. The expression of RECK mRNA in HCC tissues. (A)The RECK mRNA was indicated in HCC and Non-Hcc samples. Data are 
shown by the Mean -∆CT and 95%CI. The RECK mRNA in HCC was lower than that in the matched Non-Hcc tissues (p = 0.005). (B,C) 
There was a decreased tendency for RECK expression from Non-Hcc tissues to HCC. Expression of RECK was elevated (-∆∆Ct>=0) in 





Association of RECK mRNA with clinicopath-
ologic features 
The  relationship  between  RECK  mRNA  status 
and known clinicopathologic factors in 74 tumor tis-
sues were examined. Initially analyzed were the as-
sociations between mRNA status and available clini-
cal information including age, gender, differentiation 
of the tumor, presence  of hepatitis, presence of cir-
rhosis,  tobacco,  alcohol,  AFP.  These  analyses  were 




Table 1. Correlation of clinicophthologic variables with 
RECK mRNA in HCC. 
Variable    No.(74)  Mean-∆ct ( ± SE)  P value* 
Gender  Male  65  -0.87 ( ± 0.33)  0.974 
Female  9  -0.90 ( ± 0.51)   
Age(y)  >= 50  34  -1.04 ( ± 0.37)  0.616 
< 50  40  -0.73 ( ± 0.45)   
HBV history  Yes  43  -0.52 ( ± 0.40)  0.169 
No  31  -1.36 ( ± 0.44)   
Differentiation  G1  62  -0.64 ( ± 0.33)  0.071 
G2-3  12  -2.10 ( ± 0.55)   
Cirrhosis  Yes  39  -0.75 ( ± 0.43)  0.662 
No  35  -1.01 ( ± 0.42)   
Tobacco  Yes  33  -0.87 ( ± 0.44)  0.984 
No  41  -0.88 ( ± 0.41)   
Alcohol  Yes  14  -0.38 ( ± 0.75)  0.431 
No  60  -0.99 ( ± 0.33)   
HBV  
(copy/ml) 
>= 105  25  -1.09 ( ± 0.55)  0.601 
< 105  49  -0.76 ( ± 0.35)   
AFP 
(µg/ l) 
>= 30  45  -0.40 ( ± 0.37)  0.072 
< 30  29  -1.50 ( ± 0.49)   






There was no other significant correlation found 
between clinicopathological factors and RECK mRNA 
in Chinese HCC. The survival of these patients was 
compared by the Kaplan–Meier method and the log 
rank test (Fig. 2). We found the decreased Expression 
of RECK (-∆∆Ct<0) were significantly correlated with 
poor overall survival (p = 0.0003; HR=0.336, 95% CI: 
0.19-0.60). These results suggested that RECK mRNA 
level could be prognostic factors in HCC. 
 
Fig.2.  RECK  mRNA  associated  with  poor  prognosis  in  HCC. 
Kaplan–Meier analysis of survival months after surgery according 
to  RECK  mRNA  level.  The  decreased  Expression  of  RECK 
(-∆∆Ct<0) were significantly correlated with poor overall survival 
after surgery. 
 
Methylation status of RECK promoter in HCC 
and its adjacent tissue  
The methylation status of RECK promoter region 
was  analysed  as  one  of  the  putative  regulatory 
mechanisms of RECK mRNA expression in HCCs and 
their adjacent normal tissues. The hypermethylation 
contains  only  methylated  PCR  product,  the  partial 
methylation  contains  both  methylated  and  un-
methylated  PCR  products,  and  the  unmethylation 
contains  only  unmethylated  product  [17].  RECK 
promoter  was  hypermethylated  in  55.4%  (41/74)  of 
HCCs,  and  in  17.6%  (13/74)  of  Non-Hcc  samples; 
partial methylated in 29.7% (22/74) vs 55.4% (41/74); 
unmethylated in 14.9% (11/74) vs 27.0% (20/74). The 
difference of RECK methylation between the tumour 
and Non-Hcc groups was statistically significant (p < 
0.0001) (Fig 3).  
Association of RECK methylation with RECK 
mRNA expression in HCC and corresponding 
Non-Hcc tissues 
To test whether RECK promoter methylation in 
HCC  might  be  correlated  with  repression  of  RECK 
mRNA transcription, qPCR was used for the expres-
sion  of  RECK  transcripts  in  all  tissue  samples.  We 
found  that  RECK  methylation  is  correlated  signifi-
cantly with RECK mRNA expression, and there is a 
decreased tendency for RECK mRNA in HCC patients 
with promoter hypermethylation (R2 Linear = 0.117, p 





Fig. 3. The methylation frequency of RECK promoter in HCC 
patients by MSP. Representative H&E staining in HCC (A) and the 
matched Non-Hcc tissues (B). (C) Methylation of RECK promoter 
in HCC and corresponding Non-Hcc tissues. M, hypermethyla-
tion; PM, partial methylation; U, unmethylation; (D) Representa-
tive patterns of RECK promoter methylation. U, reaction specific 
for unmethylated DNA; M, reaction specific for methylated DNA. 
-∆Ct, - (CTRECK - CTβ-actin). 
 
The levels of RECK mRNA expression were sig-
nificantly decreased in HCC samples with methyla-
tion (∆MI>=0.5) than in those with hypomethylation 
(∆MI<0.5) (Mean -∆Ct ± SE, -1.75 ± 0.44 and 0.05 ± 0.35, 
respectively; p = 0.002; Fig. 3B). The results suggested 
that HCC showing  hypermethylation of  RECK pro-
moter may lead to silencing of RECK mRNA. 
RECK mRNA by 5-Aza-CdR and TSA 
To analyze the effects of epigenetic inhibitor on 
RECK gene expression, Real-time PCR analyses were 
performed  using  liver  cell  lines  (7721,  Chang  and 
Hep-G2)  treated  with  final  concentration  of  10  µM 
5-Aza-CdR  and  400  ng/ml  TSA.  After  normalizing 
mRNA  levels  to  β-actin,  a  1.6-2.4  ∆Ct  induction  of 
RECK  mRNA  was  detected  after  5-Aza-CdR  treat-
ment  in  Chang  and  7721  cells,  but  decrease  for 
Hep-G2 cells (Fig. 5A). Additionally, qRT-PCR assays 
found that the expression of RECK gene was induced 
3.2-6.9 ∆Ct after TSA treatment in Hep-G2 and Chang 
cells,  and  undetectable  in  7721  cells.  For  the 
5-Aza-CdR + TSA treatment, we found that a 1.4-4.4 
∆Ct induction of RECK mRNA was detected in three 
cells. Taken together, the above results suggested that 
the  expression  of  RECK  can  be  activated  by 
5-Aza-CdR or TSA, and the effect on RECK expression 
is very various for different cells. 
We  also  examined  promoter  methylation  of 
RECK in liver cell lines. Meanwhile, we observed the 
effects of 5-aza-CdR and TSA on promoter methyla-
tion of RECK gene by MSP. The RECK promoter was 
found to be hypermethylated in 7721 and Chang, but 
partial methylation in HepG2 cells (Figure 5B). The 
demethylation of RECK was found by 5-aza-CdR or 
TSA treatment in three cells. However, it showed dif-
ferent effects on RECK methylation. These data sug-
gested the demethylation of RECK promoter by epi-
genetic  inhibitor  could  play  an  important  role  for 
restoration of RECK expression. 
Discussion 
The RECK gene is widely expressed in normal 
human  tissues  but  is  downregulated  in  tumor  cell 
lines.  RECK  encodes  a  membrane-anchored  glyco-
protein  that  suppresses  tumor  invasion  and  angio-
genesis by regulating matrix-metalloproteinases [18]. 
Understanding  of  the  transcriptional  regulation  of 
RECK constitutes a potent approach to the molecular 
basis  of  liver  malignant.  DNA  methylation  of  the 
RECK  promoter  and  histone  acetyla-
tion/deacetylation have been studied to understand 
the underlying mechanisms of RECK expression [19]. 
RECK gene is a common negative target for on-
cogenic signals and that its downregulation is a step 
in  the  pathway  towards  malignant  conversion.  Our 
study confirmed that RECK was lower expression in 
HCC tissues than corresponding Non-Hcc tissues by 
Real-time PCR. Meanwhile, 24 of HCC patients were 
elevated  for  RECK  mRNA,  and  50  cases  were  de-
creased for RECK mRNA. RECK mRNA was a statis-
tically  significant  difference  between  HCC  and 
Non-Hcc tissues. However, the loss of RECK mRNA 
could play an important role in the pathogenesis of 




closely related to tumor invasion and metastasis, but 
there is no difference significantly between the level of 
RECK and clinical factors in our HCC patients. Our 
findings implied that HCC patients with high RECK 
mRNA  expression  tended  to  show  better  survival, 
which support that the feasibility of RECK mRNA as a 
promising  prognostic  molecular  marker  for  HCC. 
These results support the view that RECK is an im-
portant tumor suppressor gene. 
 
 
Fig. 4. RECK mRNA and promoter methylation in HCC patients. 
(A) The scatter plots summarized relative expression levels of 
RECK mRNA (-∆∆CT) associated with relative methylation index 
(∆MI) in HCC patients. (B) RECK mRNA expression were lower 
in HCC patients with ∆MI>= 0.5 than those with ∆MI<0.5. Sta-
tistical analyses were done using the unpaired t test. Statistical 
analyses  were  done  using  Pearson  correlation  test.  -∆∆CT,  - 
(∆CTHCC-∆CTNon-Hcc); ∆MI, MIHCC-MINon-Hcc. 
 
Fig.5.  Effect  of  5-aza-CdR  and  TSA  on  expression  of  RECK 
mRNA in liver cell lines. (A) The RECK mRNA was detected by 
real-time  PCR  for  7721,  Chang,  and  Hep-G2  treated  with 
5-aza-CdR, TSA, alone or combination. (B) It indicated that RECK 
demethylation induced significantly by TSA or TSA in 7721, Chang 
and Hep-G2 cells. 
 
 
Aberrant CpG methylation is common in cancer 
development and may play an important role in the 
carcinogenic process. Recent studies have also shown 
that RECK methylation is associated with increase of 
metastasis  and  invasion  in  human  cancers.  The  hy-
permethylation of RECK is associated with a low level 
of mRNA expression in oral squamous cell carcinoma 
cell lines [12]. We found that the frequency of RECK 
hypermethylation was higher in HCC samples than in 
non-tumor tissues, and more unmethylation of RECK 
in  corresponding  normal  tissues.  Meanwhile,  the 
RECK mRNA expression were significantly decreased 
in  HCC  samples  with  hypermethylation  (∆MI>=0) 
than  in  those  with  hypomethylation  (∆MI>=0).  The 
results suggested that HCC showing hypermethyla-
tion of RECK promoter may lead to silencing of RECK 
mRNA. This study implied also that RECK expression 
could be regulated by DNA methylation in the pro-
moter region in HCC.  
DNMT inhibitor could reverse promoter meth-
ylation and restores related gene expression in human 
cancer  cell  Lines  [20].  DNMT  inhibitor  may  restore 
RECK  expression  to  inhibit  cell  invasion  in  colon 
cancer  and  lung  cancer  cell  lines  [11,  15].  EGCG,  a 
major  component  of  green  tea,  also  may  enhance 




RECK promoter and inhibit MMP activities as well as 
cancer cell invasion in OSCC cell lines  [21]. DNMT 
inhibitors  may  be  useful  for  the  treatment  of 
RAS-induced metastasis by restored RECK expression 
[22]. And HDAC inhibitors, TSA, up-regulated RECK 
via  transcriptional  activation  in  CL-1  human  lung 
cancer cells or restored the expression of RECK under 
hypoxic conditions [23, 24]. Our results showed that 
liver cells treated with 5-Aza-CdR or TSA gave a dif-
ferent change in RECK mRNA. The 5-Aza-CdR alone 
treatment was more effective in 7721 and Chang than 
Hep-G2. The TSA alone treatment was more effective 
in Chang and Hep-G2 than 7721. And the combina-
tion treatment has a change on three cells. Meanwhile, 
we observed the different effects of epigenetic inhibi-
tors  on  promoter  demethylation  of  RECK  gene  in 
three cells.  
Taken together, RECK promoter hypermethyla-
tion is frequently observed in HCC and is associated 
with loss of mRNA expression, and decreased RECK 
mRNA is significantly correlated with worse survival 
in HCC. Additional work is needed to determine the 
mechanism  of  promoter  methylation  and  RECK 
mRNA in liver tumourigenesis. 
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